Cargando…

Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study

This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 su...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xun, Zhang, Lemeng, Chen, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914085/
https://www.ncbi.nlm.nih.gov/pubmed/29696151
http://dx.doi.org/10.1515/med-2018-0022
_version_ 1783316645950783488
author Yu, Xun
Zhang, Lemeng
Chen, Jianhua
author_facet Yu, Xun
Zhang, Lemeng
Chen, Jianhua
author_sort Yu, Xun
collection PubMed
description This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin. The patients received 2 cycles of treatment (21 days/cycle). The clinical efficacy and adverse events were observed and compared. The disease control rate in the combination group was significantly higher compared with the chemotherapy group (P < 0.05). When comparing the cases of squamous carcinoma, the disease control rate in the combination group was significantly higher than the chemotherapy group (P < 0.05). Moreover, the progression free survival in the combination group was higher than that for the chemotherapy group, with a statistically significant difference (P < 0.05). The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated.
format Online
Article
Text
id pubmed-5914085
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher De Gruyter Open
record_format MEDLINE/PubMed
spelling pubmed-59140852018-04-25 Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study Yu, Xun Zhang, Lemeng Chen, Jianhua Open Med (Wars) Regular Articles This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin. The patients received 2 cycles of treatment (21 days/cycle). The clinical efficacy and adverse events were observed and compared. The disease control rate in the combination group was significantly higher compared with the chemotherapy group (P < 0.05). When comparing the cases of squamous carcinoma, the disease control rate in the combination group was significantly higher than the chemotherapy group (P < 0.05). Moreover, the progression free survival in the combination group was higher than that for the chemotherapy group, with a statistically significant difference (P < 0.05). The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated. De Gruyter Open 2018-04-19 /pmc/articles/PMC5914085/ /pubmed/29696151 http://dx.doi.org/10.1515/med-2018-0022 Text en © 2018 Xun Yu et al. http://creativecommons.org/licenses/by-nc-nd/4.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
spellingShingle Regular Articles
Yu, Xun
Zhang, Lemeng
Chen, Jianhua
Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title_full Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title_fullStr Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title_full_unstemmed Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title_short Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
title_sort effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study
topic Regular Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914085/
https://www.ncbi.nlm.nih.gov/pubmed/29696151
http://dx.doi.org/10.1515/med-2018-0022
work_keys_str_mv AT yuxun effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy
AT zhanglemeng effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy
AT chenjianhua effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy